Camp4 Therapeutics Corporation logo

Camp4 Therapeutics Corporation (CAMP)

Market Open
26 Oct, 07:35 PM
NASDAQ (NMS) NASDAQ (NMS)
$
3. 21
-0.09
-2.6515%
$
198.93M Market Cap
- P/E Ratio
- Div Yield
38,349 Volume
-5.27 Eps
$ 3.3
Previous Close
Add Transaction
Day Range
3.19 3.32
Year Range
2.9 7.75
Want to track CAMP and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

CAMP trading today lower at $3.21, a decrease of -2.6515% from yesterday's close, completing a monthly decrease of -16.5584% or -$0.64. Over the past 12 months, CAMP stock lost -48.3521%.
CAMP is not paying dividends to its shareholders.
The last earnings report, released on May 19, 2026, exceeded the consensus estimates by 0.21%. On average, the company has surpassed earnings expectations by 0.0636%, based on the last three reports.
Camp4 Therapeutics Corporation has completed 2 stock splits, with the recent split occurring on Feb 02, 2024.
The company's stock is traded on one exchange.

CAMP Chart

People also search for

Arcturus Therapeutics Holdings Inc.
$ 9.89
+0.5142%
Artiva Biotherapeutics, Inc.
$ 6.14
-0.1268%
Fulcrum Therapeutics, Inc.
$ 3.65
-0.9511%
KraneShares Global Humanoid and Embodied Intelligence Index ETF
$ 33.9
+2.0777%
EyePoint, Inc. Common Stock
$ 0.37
-8.529%
CAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic Disease

CAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic Disease

Korro and Tevard outlined approaches designed to expand the therapeutic use of RNA medicines beyond protein silencing, highlighting programs that aim to repair genetic defects or restore production of full-length proteins.

Marketbeat | 6 days ago
Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript

Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript

Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript

Seekingalpha | 3 weeks ago
CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002

CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002

CAMP4 Therapeutics NASDAQ: CAMP said it expects to dose the first patient in its Phase I/II ASCEND trial of CMP-002 for SYNGAP1-related disorder during the fourth quarter, with top-line results targeted for the first half of 2028.

Marketbeat | 4 weeks ago

Camp4 Therapeutics Corporation Investors

Name Quantity Cost Value Profit ($) Gain (%)
DS
Danny Salinas Cantor Fitzgerald LP
53,500 $237,540 $174,586.55 -$62,953.45 -26.5%
KM
Kristin Mariani Janus Henderson Group PLC
6.31M $24.18M $20.66M -$3.52M -14.56%
CD
Charlie Durham Sterling Capital Management LLC
1,038 $4,230.51 $3,383.88 -$846.63 -20.01%
Joseph Castro
Joseph Castro Nuveen LLC
42,048 $183,750 $136,656 -$47,094 -25.63%
Li Peng
Li Peng China Universal Asset Management Co. Ltd.
800 $3,528 $2,575.44 -$952.56 -27%

Camp4 Therapeutics Corporation (CAMP) FAQ

What is the stock price today?

The current price is $3.21.

On which exchange is it traded?

Camp4 Therapeutics Corporation is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is CAMP.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 198.93M.

Has Camp4 Therapeutics Corporation ever had a stock split?

Camp4 Therapeutics Corporation had 2 splits and the recent split was on Feb 02, 2024.

Camp4 Therapeutics Corporation Profile

Biotechnology Industry
Healthcare Sector
Joshua Mandel-Brehm CEO
NASDAQ (NMS) Exchange
13463J101 CUSIP
US Country
48 Employees
- Last Dividend
2 Feb 2024 Last Split
7 Sep 1984 IPO Date

Overview

CalAmp Corp. is a connected intelligence company that crafts and delivers data-driven solutions to individuals and organizations globally. With operations spanning the United States, Europe, the Middle East, Africa, Latin America, and the Asia-Pacific, CalAmp makes use of an extensive solutions ecosystem to enhance data utility for its customers. The company divides its offerings into two main segments: Software & Subscription Services and Telematics Products. These solutions are targeted towards enhancing operations in diverse sectors such as automotive, telecommunications, industrial equipment, transportation, logistics, government, insurance, and more. Founded in 1981, CalAmp is based in Irvine, California, and propels its market reach through a combination of direct sales, channel partners, OEM relationships, and online platforms.

Products and Services

CalAmp Telematics Cloud: A comprehensive, cloud-based platform that enables the integration of both CalAmp's applications and those developed by third parties through its open APIs. This service offers a robust foundation for deploying telematics solutions that cater to fleet management, supply chain integrity, and vehicle location on an international scale.

Software as a Service (SaaS) Applications: Delivers web-based applications that provide tracking and monitoring functionalities for fleets, asset management, and supply chain oversight. These services are designed to improve operational efficiency and ensure integrity along the entire supply chain.

Telematics Products: Includes a variety of hardware devices such as asset tracking units, mobile telematics devices, wireless gateways, and routers designed for both fixed and mobile applications. These products serve the critical function of collecting, monitoring, and communicating important information from assets in the field, thereby enabling businesses to optimize their operations.

Advanced Telematics for Connected Vehicles and IoT: Offers sophisticated products that cater to the needs of the evolving connected vehicle and Internet of Things (IoT) markets. These innovations allow for the collection of business-critical data and intelligence, facilitating improved decision-making and operational efficiencies across various industries.

Professional Services: Beyond its product lineup, CalAmp provides tailored professional services including project management, engineering support, and installation services to ensure the successful deployment and utilization of its solutions.

Contact Information

Address: One Kendall Square Bldg 1400 West, 3rd Floor
Phone: 617-651-8867